Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVC-COV1901 in elderly adults
NCT04822025Phase 2Completed
- Sponsor
- Medigen Biotechnology
- Start
- May 2021
- Primary completion
- Aug 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MVC-COV1901 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Medigen Biotechnology. Primary endpoints: Incidence of Adverse Events and Immunogenicity of MVC-COV1901. Started May 2021; status: completed.
02
Drugs
MVC-COV1901
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04822025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04822025.